TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16525941

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 1010

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Combined therapy (Bisoprolol + Enalapril)
Number of subjects: 1010
Study: 11868011

Group type: EXPERIMENTAL
Intervention: Argon plasma coagulation (APC) applied to the rim and any residual mucosal or submucosal tissue in the base of the polypectomy site.
Number of subjects: 34

Group type: COMPARATOR
Intervention: No further therapy (control) after piecemeal snare resection.
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Argon plasma coagulation (APC) applied to all visible remaining adenomatous tissue in patients with incomplete excision.
Number of subjects: 34
Study: 11431662

Group type: EXPERIMENTAL
Intervention: Late sustained ventricular tachycardia
Number of subjects: 16842

Group type: COMPARATOR
Intervention: No late sustained ventricular tachycardia (reference group)
Number of subjects: 16842
Study: 9589654

Group type: EXPERIMENTAL
Intervention: Sodium replete diet (160 mmol/day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sodium deplete diet (40 mmol/day)
Number of subjects: 8
Study: 8055694

Group type: EXPERIMENTAL
Intervention: Naphcon-A (naphazoline HCl 0.025% and pheniramine maleate 0.3%)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72

Group type: COMPARATOR
Intervention: Naphazoline
Number of subjects: 72

Group type: COMPARATOR
Intervention: Pheniramine
Number of subjects: 72
Study: 2923768

Group type: EXPERIMENTAL
Intervention: isoflurane
Number of subjects: 48

Group type: COMPARATOR
Intervention: halothane
Number of subjects: 48
Study: 793524

Group type: EXPERIMENTAL
Intervention: UV irradiation with 1% CCT ointment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UV irradiation with 6% CCT ointment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UV irradiation with ointment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1% CCT ointment and UV irradiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-concentration (6%) tar ointment without UV irradiation
Number of subjects: 0
Study: 30264521

Group type: EXPERIMENTAL
Intervention: Occupation-centred education
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Theoretical models endorsed by educators
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Innovative approaches in education
Number of subjects: 8
Study: 28406788

Group type: COMPARATOR
Intervention: Disease-modifying agents (DMAs) with varying characteristics including dosage type, efficacy, relapse risk, and side effects.
Number of subjects: 0
Study: 25218667

Group type: EXPERIMENTAL
Intervention: Weight loss (at least 5% decrease in BMI)
Number of subjects: 43

Group type: COMPARATOR
Intervention: No weight loss (less than 5% decrease in BMI)
Number of subjects: 43
Study: 23994379

Group type: EXPERIMENTAL
Intervention: Schwarz measles vaccine (SW)
Number of subjects: 996

Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb measles vaccine (EZ)
Number of subjects: 996

Group type: EXPERIMENTAL
Intervention: Booster dose at 18 months (same MV)
Number of subjects: 996

Group type: EXPERIMENTAL
Intervention: Non-protective antibody levels
Number of subjects: 996

Group type: EXPERIMENTAL
Intervention: Gender comparison after EZ
Number of subjects: 996

Group type: EXPERIMENTAL
Intervention: Seasonal comparison
Number of subjects: 996
Study: 21606827

Group type: EXPERIMENTAL
Intervention: Succinylcholine (1.5 mg/kg)
Number of subjects: 70
Study: 19731967

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Natalizumab (NZ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Symptom management alone
Number of subjects: 0
Study: 16788411

Group type: EXPERIMENTAL
Intervention: Patellar tilt test
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Active instability test
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Patella alta test
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Apprehension test
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Quadriceps angle, lateral and medial retinacular tenderness, patellofemoral crepitation, squinting patella, and reduced mobility of the patella
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Plain radiography
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Other radiographic measures (sulcus angle, Laurin angle, Merchant angle, Insall‐Salvati index)
Number of subjects: 61
Study: 15497256

Group type: EXPERIMENTAL
Intervention: Concurrent memory task present
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Instruction to focus on memory
Number of subjects: 0

Group type: COMPARATOR
Intervention: Instruction to focus on timing
Number of subjects: 0
Study: 11430720

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) therapy
Number of subjects: 25
Study: 10168576

Group type: EXPERIMENTAL
Intervention: Experimental group (E) - received usual clinic information plus a prenatal and postpartum intervention
Number of subjects: 391

Group type: COMPARATOR
Intervention: Control group (C) - received only usual clinic information
Number of subjects: 391
Study: 8436517

Group type: EXPERIMENTAL
Intervention: Low dose rate 0.73 Gy.h‐1
Number of subjects: 204

Group type: COMPARATOR
Intervention: Low dose rate 0.38 Gy.h‐1
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Higher dose rate group (0.73 Gy.h‐1)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Lower dose rate group (0.38 Gy.h‐1)
Number of subjects: 204
Study: 3453705

Group type: EXPERIMENTAL
Intervention: Ribomunyl (active medicine)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 24
Study: 31885863

Group type: EXPERIMENTAL
Intervention: 3 Tesla scanner
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Low-pass filtering of time series
Number of subjects: 3

Group type: COMPARATOR
Intervention: 1.5 Tesla scanner
Number of subjects: 3
Study: 30145268

Group type: EXPERIMENTAL
Intervention: Doxazosin (16 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26716865

Group type: EXPERIMENTAL
Intervention: Lung protective ventilation strategy (low tidal volume, PEEP between 6 and 8 cmH2O, recruitment manoeuvres)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Non-protective ventilation strategy (higher tidal volume, zero PEEP, no recruitment manoeuvres)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Non-protective ventilation strategy
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Lung protective ventilation strategy
Number of subjects: 79
Study: 25134530

Group type: EXPERIMENTAL
Intervention: Evidence-based patient information (EBPI)
Number of subjects: 1120

Group type: COMPARATOR
Intervention: Standard on-line information (Control)
Number of subjects: 1120
Study: 22290107

Group type: EXPERIMENTAL
Intervention: Doxycycline-rifampin
Number of subjects: 181

Group type: COMPARATOR
Intervention: Doxycycline-rifampin-gentamicin
Number of subjects: 181
Study: 20370962

Group type: EXPERIMENTAL
Intervention: Various treatment monotherapies, combinations, or augmentation strategies (specifics not detailed)
Number of subjects: 2876
Study: 17019375

Group type: EXPERIMENTAL
Intervention: Soy protein-containing isoflavones
Number of subjects: 216

Group type: COMPARATOR
Intervention: Casein placebo
Number of subjects: 216
Study: 15906588

Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg once daily for 14 days
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg once daily for 14 days
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg and 10 mg
Number of subjects: 47
Study: 12654606

Group type: EXPERIMENTAL
Intervention: Tirofiban administered in the emergency room
Number of subjects: 100

Group type: COMPARATOR
Intervention: Tirofiban administered later in the catheterization laboratory
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tirofiban (early administration)
Number of subjects: 100
Study: 10473830

Group type: EXPERIMENTAL
Intervention: Radical neck dissection after initial chemotherapy and between two courses of locoregional radiotherapy (group A)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Surgery after finishing chemotherapy and locoregional radiotherapy (group B 1)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Surgery after receiving only full-dose locoregional radiotherapy (group B 2)
Number of subjects: 44
Study: 8733854

Group type: EXPERIMENTAL
Intervention: Topical anesthesia
Number of subjects: 36

Group type: COMPARATOR
Intervention: Peribulbar anesthesia
Number of subjects: 36
Study: 1717776

Group type: EXPERIMENTAL
Intervention: Combination of benazepril (10 mg) and cadralazine (5 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Benazepril (10 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cadralazine (5 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combination of benazepril and cadralazine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 6355533

Group type: EXPERIMENTAL
Intervention: Verapamil hydrochloride, 80 mg four times daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 4003239

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Atenolol 200 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Atenolol (all doses combined)
Number of subjects: 25
Study: 29134277

Group type: EXPERIMENTAL
Intervention: 16.5/17.5 Fr Miniperc (group A)
Number of subjects: 123

Group type: COMPARATOR
Intervention: 22/24 Fr standard PCNL (group B)
Number of subjects: 123
Study: 26442902

Group type: EXPERIMENTAL
Intervention: Citrate dialysate (CiDi)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard dialysate (StDi)
Number of subjects: 92
Study: 24569536

Group type: EXPERIMENTAL
Intervention: Probiotic yoghurt
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Probiotic capsules
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control milk
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 156
Study: 22424822

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice daily for 12 weeks)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 19657590

Group type: EXPERIMENTAL
Intervention: 1 microg alfacalcidol (D)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: 60 mg raloxifene (R)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Combination of 1 microg alfacalcidol and 60 mg raloxifene (D + R)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: High-compliance patients (MPR > 80%) treated with raloxifene alone or with alfacalcidol
Number of subjects: 137
Study: 18754270

Group type: EXPERIMENTAL
Intervention: simvastatin 80 mg + ezetimibe 10 mg
Number of subjects: 720

Group type: COMPARATOR
Intervention: simvastatin 80 mg + placebo
Number of subjects: 720
Study: 16869135

Group type: EXPERIMENTAL
Intervention: Friction braked cycle ergometry with resistive forces reflecting fat-free mass (FFM)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Friction braked cycle ergometry with resistive forces reflecting total-body mass (TBM)
Number of subjects: 11
Study: 11273847

Group type: EXPERIMENTAL
Intervention: Soy+ protein (80 mg aglycone isoflavones, 42 g/d)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Soy- protein (trace amounts of isoflavones, 42 g/d)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Milk protein (42 g/d)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 94
Study: 9555964

Group type: EXPERIMENTAL
Intervention: BioMedicus centrifugal pump (CP)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: roller pump
Number of subjects: 1000
Study: 8296708

Group type: EXPERIMENTAL
Intervention: ANF (2 micrograms/kg intravenously) plus furosemide (1.3 mg/kg intravenously)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo plus furosemide (1.3 mg/kg intravenously)
Number of subjects: 14
Study: 3190990

Group type: EXPERIMENTAL
Intervention: Bupivacaine HCl 1.4 mg kg‐1 by i.m. injection after no premedication
Number of subjects: 7

Group type: COMPARATOR
Intervention: Bupivacaine HCl 1.4 mg kg‐1 by i.m. injection after two oral doses of 400 mg cimetidine
Number of subjects: 7
Study: 29211967

Group type: EXPERIMENTAL
Intervention: AMPH EROS (10-20 mg/day)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 26969128

Group type: EXPERIMENTAL
Intervention: The Feeling Safe Programme
Number of subjects: 150

Group type: COMPARATOR
Intervention: Befriending (control)
Number of subjects: 150
Study: 24803285

Group type: EXPERIMENTAL
Intervention: 6-week structured cognitive training program
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study: 22497790

Group type: EXPERIMENTAL
Intervention: Longer dialysis catheters (20-24 cm)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Shorter dialysis catheters (15-20 cm)
Number of subjects: 100
Study: 20233525

Group type: EXPERIMENTAL
Intervention: Closed circuit (CC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Semi-closed circuit (SCC) at 4 l/min
Number of subjects: 60

Group type: COMPARATOR
Intervention: Semi-closed circuit (SCC) at 2 l/min
Number of subjects: 60
Study: 18576922

Group type: EXPERIMENTAL
Intervention: 20-minute massage
Number of subjects: 14

Group type: COMPARATOR
Intervention: 20-minute reading period (control)
Number of subjects: 14
Study: 15801245

Group type: EXPERIMENTAL
Intervention: Desloratadine-pseudoephedrine, 5/240-mg tablets
Number of subjects: 1121

Group type: COMPARATOR
Intervention: Desloratadine, 5 mg
Number of subjects: 1121

Group type: COMPARATOR
Intervention: Pseudoephedrine, 240 mg
Number of subjects: 1121
Study: 12428229

Group type: EXPERIMENTAL
Intervention: Joint distraction
Number of subjects: 57
Study: 10543296

Group type: EXPERIMENTAL
Intervention: L-NMMA
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7787145

Group type: EXPERIMENTAL
Intervention: Intensive Group #1, MAP < or = 92 mm Hg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moderate Group #2, MAP 100 to 107 mm Hg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Captopril (previous study)
Number of subjects: 0
Study: 2194055

Group type: EXPERIMENTAL
Intervention: Rokitamycin (RKM) dry syrup at approximately 30 mg/kg body weight for 5 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fosfomycin (FOM) dry syrup at 60 mg/kg body weight for 5 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rokitamycin (RKM) dry syrup
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fosfomycin (FOM) dry syrup
Number of subjects: 0
Study: 361512

Group type: EXPERIMENTAL
Intervention: Deglycyrrhizinised liquorice
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 29501108

Group type: EXPERIMENTAL
Intervention: Active AcceleDent Aura device (OrthoAccel Technologies, Inc.)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sham AcceleDent Aura device
Number of subjects: 27
Study: 27044326

Group type: EXPERIMENTAL
Intervention: Vilanterol (VI) 25 μg
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Vilanterol (VI) 6.25 μg and VI 12.5 μg
Number of subjects: 456

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Vilanterol (VI) 6.25 μg, VI 12.5 μg, VI 25 μg
Number of subjects: 456

Group type: COMPARATOR
Intervention: Placebo plus fluticasone propionate (FP)
Number of subjects: 456
Study: 24948656

Group type: EXPERIMENTAL
Intervention: Nilotinib (400 mg twice daily)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Imatinib
Number of subjects: 207
Study: 22885502

Group type: EXPERIMENTAL
Intervention: Split-root extraction
Number of subjects: 40

Group type: COMPARATOR
Intervention: Medial resistance removal
Number of subjects: 40
Study: 19933173

Group type: EXPERIMENTAL
Intervention: Open lung ventilation (recruitment manoeuvres, tidal volume 6 ml kg(‐1) predicted body weight, and 12 cm H(2)O PEEP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional ventilation (no recruitment manoeuvres, tidal volume 10 ml kg(‐1) predicted body weight, and zero end‐expiratory pressure)
Number of subjects: 40
Study: 17367351

Group type: EXPERIMENTAL
Intervention: Pacing at RAA using up to 10 consecutive 20-Hz trains followed by pacing at CS-Os if RAA pacing failed
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Pacing at CS-Os using the same stimulation protocol followed by HF pacing at RAA
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: HF pacing at CS-Os
Number of subjects: 110

Group type: COMPARATOR
Intervention: Observation up to 6 minutes (no pacing)
Number of subjects: 110
Study: 15613434

Group type: EXPERIMENTAL
Intervention: Estradiol (E(2))
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 13
Study: 12172049

Group type: EXPERIMENTAL
Intervention: 2% lincomycin mixed with 0.05% betamethasone valerate and 2% linoleic acid (group C)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 2% lincomycin mixed with 0.05% betamethasone valerate (group B)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Vehicle (group A)
Number of subjects: 47
Study: 10608202

Group type: EXPERIMENTAL
Intervention: Diltiazem (11.4 +/- 0.9 microg x kg(‐1) x min(‐1))
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nicardipine (8.1 +/- 0.8 microg x kg(‐1) x min(‐1))
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combination of diltiazem (0.25 +/- 0.01 mg x kg(‐1)) and nicardipine (5.9 +/- 0.9 microg x kg(‐1) x min(‐1))
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Group N (Nicardipine)
Number of subjects: 36
Study: 7723960

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 20
Study: 2040131

Group type: EXPERIMENTAL
Intervention: Thermography
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Laser-Doppler flowmetry (LDF)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Smoking two 1.1 mg nicotine cigarettes
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Comparison of maximum responses during a 45-min period after smoking
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Reproducibility of responses
Number of subjects: 24
Study: 6104615

Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg for 3 weeks
Number of subjects: 0
Study: 30392112

Group type: EXPERIMENTAL
Intervention: Supportive care intervention with usual care
Number of subjects: 28

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 28
Study: 27839965

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) gel therapy (2mL/cm2 of ulcers), performed weekly for 4 weeks
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) gel therapy
Number of subjects: 70
Study: 25641535

Group type: EXPERIMENTAL
Intervention: Cardiac troponin I (cTnI) measured at various time points post-PCI
Number of subjects: 1066

Group type: EXPERIMENTAL
Intervention: cTnI added to baseline risk model
Number of subjects: 1066
Study: 24379229

Group type: EXPERIMENTAL
Intervention: SCAMP nutrition (12% glucose, 3.8 g/kg per day protein/lipid)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control PN (10% glucose, 2.8 g/kg per day protein/lipid)
Number of subjects: 150
Study: 20861716

Group type: EXPERIMENTAL
Intervention: Medical food (Theramine) alone (n = 43)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Naproxen alone (250 mg/d, n = 42)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Medical food (Theramine) with naproxen (n = 44)
Number of subjects: 129
Study: 19503811

Group type: EXPERIMENTAL
Intervention: Thiazolidinedione (glitazone)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Comparator drug
Number of subjects: 61

Group type: COMPARATOR
Intervention: Higher impact factor journals
Number of subjects: 61
Study: 17462946

Group type: EXPERIMENTAL
Intervention: Tricuspid annular plane systolic excursion (TAPSE) measurement
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: Presence of chronic obstructive pulmonary disease (COPD)
Number of subjects: 817
Study: 15064872

Group type: EXPERIMENTAL
Intervention: 99mTc-TRODAT-1 (TR)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 123I-FP-beta-CIT (FP)
Number of subjects: 96
Study: 11809253

Group type: EXPERIMENTAL
Intervention: Smoking intervention (counselling and nicotine replacement therapy, with smoking cessation or at least 50% smoking reduction)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Smoking intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control
Number of subjects: 120
Study: 9524512

Group type: EXPERIMENTAL
Intervention: 120 degrees fixed angle blade‐plate (group A)
Number of subjects: 233

Group type: COMPARATOR
Intervention: 135 degrees compression hip screw (group B)
Number of subjects: 233
Study: 1439512

Group type: EXPERIMENTAL
Intervention: Takeda Medical (A & D) TM 2420
Number of subjects: 85

Group type: COMPARATOR
Intervention: Hawksley random-zero sphygmomanometer
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: TM 2420
Number of subjects: 85
Study: 3739807

Group type: EXPERIMENTAL
Intervention: Abstinence goal preference
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Personal persuasion indicators
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Dependence indicators
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: SADQ scores and Rand definite alcoholism
Number of subjects: 46
Study: 31567304

Group type: EXPERIMENTAL
Intervention: Progressive Relaxation Exercises (PRE)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 96
Study: 30027429

Group type: EXPERIMENTAL
Intervention: G‐chemo
Number of subjects: 123

Group type: COMPARATOR
Intervention: R‐chemo
Number of subjects: 123
Study: 27702715

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (CC treatment, 65 mg caffeine/cup)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Decaffeinated coffee (DC treatment, 99.9% caffeine‐free)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Boiled water (BW treatment)
Number of subjects: 42
Study: 25108590

Group type: EXPERIMENTAL
Intervention: Negative mood induction
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Neutral mood induction
Number of subjects: 80
Study: 22159820

Group type: EXPERIMENTAL
Intervention: Resistive vibration exercise (RVE)
Number of subjects: 14

Group type: COMPARATOR
Intervention: No exercise (CON)
Number of subjects: 14